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A dozen dominant genetic disorders are
caused by aberrant expansions of CAG or
CTG trinucleotide repeats. As these re-
peats are complementary sequences, the
expansions are incurred by both strands.
However, it is the genic or transcribed
strand that has defined the CAG and
CTG repeat diseases. CAG repeat–associ-
ated diseases represent a group of neuro-
logical disorders, including Huntington’s
disease, dentatorubral pallidoluysian atro-
phy, spinal and bulbar muscular atrophy,
and several spinocerebellar ataxias
(SCA1–3, 6, 7, and 17), which are all
caused by an expansion of CAG repeats in
the coding region of genes with otherwise
no other common features. The resulting
mutant, toxic proteins bear a polygluta-
mine expansion (polyQ), which is sufficient
to trigger a neuronal pathology [1]. The
propensity of polyQ-expanded proteins to
progressively misfold and aggregate ap-
pears to be doubly deleterious. First, it
impairs normal functions or turn-over of
host proteins. Second, polyQ aggregates
alter neuronal physiology by activating
stress responses or recruiting essential
components of the cellular machinery
[2]. In contrast, the CTG repeat expan-
sion responsible for myotonic dystrophy
type 1 (DM1), a multi-systemic disease
affecting mainly the muscle but also the
brain, is located in the 39-untranslated
region of the DMPK gene. The toxic entity
is the CUG-expansion transcript, which
adopts secondary structures and forms
RNA foci, thereby sequestering RNA-
binding proteins implicated in pre-mRNA
splicing [3]. Muscleblind-like (MBNL)
proteins are splicing factors whose recruit-
ment to RNA foci leads to misregulated
splicing of tissue-specific targets. In addi-
tion, CELF proteins, including CUG
binding protein 1 (CUGBP1), are up-
regulated in DM1 tissues. Both events
contribute to the reversal from adult to
fetal or developmental splicing patterns
[4]. Thus, so far, it has been widely
accepted that toxic RNA gain-of-function
and toxic protein gain-of-function mecha-
nisms underlie the distinction between
CTG and CAG repeat–associated diseases
[5]. Two articles on spinocerebellar ataxia
type 8 (SCA8) published by the group of
Laura Ranum, first in 2006 [6] and now in
this issue of PLoS Genetics [7], suggest that
this view is simplistic, deserving of atten-
tion and revision.
Since its discovery, SCA8 has been a
curiosity among triplet repeat disorders. It
was the first dominant SCA apparently
not caused by a CAG expansion–encod-
ing polyglutamine tract, as the uncovered
mutation was a CTG repeat expansion in
a transcribed gene (ATXN8OS)l a c k i n g
open reading frames (ORFs) [8]. In 2006,
Ranum and colleagues [6] designed
transgenic mice carrying a bacterial arti-
ficial chromosome (BAC) encompassing
the entire human SCA8 locus, with a
normal or expanded CTG allele. Charac-
terization of the model revealed bidirec-
tional expression of both CUG- and
CAG-expansion transcripts. Unexpected-
ly, the authors found that the CAG
transcript was translated into a nearly
pure polyQ protein that formed typical
neuronal nuclear inclusions, the specific
hallmark of polyQ diseases. The data
suggested, therefore, that the pathology
resulted, in part, from a toxic protein
gain-of-function mechanism and raised
the possibility that SCA8 could be caused
by both toxic protein and toxic RNA gain-
of-functions.
Daughters et al. now present a body of
evidence suggesting that the toxic RNA
pathomechanism substantially contributes
to SCA8 pathology [7]. The authors show
that the CUG-repeat transcripts expressed
from the SCA8 locus form RNA foci in
specific neurons in SCA8 patient and
mouse brains. In addition, MBNL1 pro-
tein colocalizes with these RNA foci.
Furthermore, the authors provide evi-
dence for a genetic interaction between
SCA8 and Mbnl1 gene loci by showing
that loss of the Mbnl1 gene in SCA8
BAC
exp mice increases the motor pheno-
type. These results extend to mice earlier
observations in flies showing that SCA8
CUG transcript expression caused toxicity
that can be modulated by mutation in
muscle-blind or three other genes encoding
RNA-binding proteins [9]. Importantly,
using cross-linking and immunoprecipita-
tion (CLIP) analysis with an anti-CUGBP1
antibody, Ranum and colleagues identify a
specific CUGBP1 RNA target, the GABA-
A transporter 4 (GAT4) transcript, which
shows up-regulation and a shift in alter-
native splicing favoring exon 7 insertion in
SCA8 mouse and patient brains, resem-
bling expression features detected in the
fetal cortex. Interestingly, these changes
are specific to SCA8 patients, as GAT4
expression and splicing pattern are normal
in DM1 brain. Finally, up-regulation of
the GAT4 gene product, which is primarily
detected in the granular cell layer of the
cerebellar cortex in the SCA8 mouse, fits
well with the increased physiological
response of granular cells to mossy fiber
inputs. The authors hypothesize that
transcript-skipping exon 7 is targeted for
nonsense-mediated decay, and that shift-
ing in exon 7 insertion in SCA8 patients
underlies GAT4 up-regulation. Together,
these data indicate that the CUG-expan-
sion transcript expressed at the SCA8
locus is indeed toxic.
Thus, both studies from Ranum’s group
provide the proof of concept that toxic
RNA and toxic protein gain-of-function
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SCA8, although the relative contribution
of each mechanism remains to be deter-
mined. The next obvious question to
address is whether bidirectional expression
of CAG- and CUG-expansion transcripts
is a general feature of CAG/CTG diseases
and whether the combined toxic effects of
RNA and protein gains-of-function could
underlie the pathomechanisms involved in
these diseases and account for their
complexities. Bidirectional expression at
the DM1 locus has been reported, but the
antisense transcript does not appear to be
translated into a polyQ protein [10]. More
puzzling is the case of Huntington’s
disease–like 2 (HDL2), a dominant inher-
ited disease closely resembling Hunting-
ton’s disease and caused by CAG/CTG
repeat expansion in the JPH3 gene [11].
While expression of CUG-expansion
JPH3 transcripts forming toxic RNA foci
was demonstrated, the presence of polyQ
aggregates was highly suggested by im-
munodetection using an antibody specifi-
cally detecting polyQ expansions, i.e., the
1C2 antibody [12,13]. If it happens that
expression of antisense CUG-expansion
transcripts is common in polyQ disorders,
undoubtedly this will open new routes of
investigation of their pathomechanism.
Specifically, such a discovery could help
to solve the issue of tissue selectivity, which
remains puzzling. Indeed, the pattern of
affected tissues correlates neither with the
pattern of expression of CAG-expansion
transcripts nor with the pattern of polyQ
neuronal inclusions. In addition, degener-
ating neurons differ between polyQ dis-
eases. For instance, the striatum preferen-
tially degenerates in Huntington’s disease,
while the cerebellum is mostly affected in
SCAs. The possible existence of antisense
CUG-expansion transcripts could underlie
some aspects of tissue selectivity. Toxic
RNA effects could add to disease patho-
mechanism complexity. The relative con-
tribution of both mechanisms (toxic RNA
versus toxic protein) could also be tissue-
or cell-specific, depending on the relative
expression level of CAG- and CUG-
expansion transcripts. Finally, data ob-
tained from SCA3 Drosophila models sug-
gested that CAG-expansion transcripts
could also be toxic [14]. In that case, the
toxicity threshold appeared to exceed 200
CAG repeats, which represent very rare
disease alleles in polyQ disorders. One
should, however, keep in mind that such
high repeat numbers might be reached in
some brain regions as a consequence of
somatic repeat instability, as is illustrated
in the case of Huntington’s disease [15].
However, while toxic CUG diseases are
typically thought to be associated with
large expansions, in the SCA8 patients
and mice studied by Ranum, the expan-
sions were relatively short—within the
range of many polyQ diseases. Thus, the
potential connection between the RNA
world and polyQ diseases now has to be
clarified.
Figure 1. Both toxic-protein (polyQ) and toxic-RNA gain-of-functions might underlie SCA8 pathogenesis. Bidirectional expression of
CAG- and CUG-transcripts at the human SCA8 locus results in production of a polyQ protein forming ubiquitinated aggregates and accumulation of
RNA foci sequestering MBNL splicing factor.
doi:10.1371/journal.pgen.1000593.g001
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